We are live on ! Find out more
SCM

Superstring Capital Management Portfolio holdings

AUM $140M
1-Year Est. Return 323.19%
This Fund
S&P 500
This Quarter Est. Return
+16.36%
1 Year Est. Return
+323.19%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$140M
AUM Growth
-$46.8M
Cap. Flow
-$52M
Cap. Flow %
-37.18%
Top 10 Hldgs %
57.92%
Holding
59
New
14
Increased
8
Reduced
12
Closed
24

Top Buys

Rank Stock Value
1
SMMT icon
Summit Therapeutics
SMMT
+$14.4M
2
PCVX icon
Vaxcyte
PCVX
+$6M
3
VIR icon
Vir Biotechnology
VIR
+$5.82M
4
VRTX icon
Vertex Pharmaceuticals
VRTX
+$5.13M
5
GMAB icon
Genmab
GMAB
+$5.02M

Top Sells

Rank Stock Value
1
CDTX
Cidara Therapeutics
CDTX
+$18.8M
2
TERN
Terns Pharmaceuticals
TERN
+$17.9M
3
DVAX
Dynavax Technologies
DVAX
+$8.08M
4
URGN icon
UroGen Pharma
URGN
+$6.64M
5
COGT icon
Cogent Biosciences
COGT
+$5.21M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ACRS icon
26
Aclaris Therapeutics
ACRS
$793M
$1.37M 0.98%
+366,490
New +$1.24M
CLYM
27
Climb Bio
CLYM
$727M
$1.36M 0.97%
+199,209
New +$1.15M
TSHA icon
28
Taysha Gene Therapies
TSHA
$1.71B
$1.15M 0.82%
258,269
-722,499
-74% -$3.36M
DRUG
29
Bright Minds Biosciences
DRUG
$747M
$971K 0.69%
13,311
-33,967
-72% -$2.73M
TNXP icon
30
Tonix Pharmaceuticals
TNXP
$198M
$874K 0.62%
+63,540
New +$978K
CGEM icon
31
Cullinan Oncology
CGEM
$1.09B
$845K 0.6%
+59,484
New +$764K
TARA icon
32
Protara Therapeutics
TARA
$230M
$633K 0.45%
121,457
-238,543
-66% -$1.41M
PTN
33
Palatin Technologies
PTN
$16.2M
$627K 0.45%
35,969
+1,998
+6% +$37.9K
BMEA icon
34
Biomea Fusion
BMEA
$92.5M
$383K 0.27%
250,000
– –
IPSC icon
35
Century Therapeutics
IPSC
$406M
$270K 0.19%
119,308
-343,655
-74% -$723K
ASMB icon
36
Assembly Biosciences
ASMB
$531M
– –
-65,273
Closed -$2.22M
AVTX icon
37
Avalo Therapeutics
AVTX
$1.02B
– –
-153,313
Closed -$2.78M
BLTE
38
Belite Bio
BLTE
$6.02B
– –
-24,703
Closed -$3.95M
CAPR icon
39
Capricor Therapeutics
CAPR
$1.13B
– –
-96,334
Closed -$2.78M
CDTX
40
DELISTED
Cidara Therapeutics
CDTX
– –
-85,098
Closed -$18.8M
DNTH icon
41
Dianthus Therapeutics
DNTH
$5.77B
– –
-26,249
Closed -$1.08M
DVAX
42
DELISTED
Dynavax Technologies
DVAX
– –
-525,592
Closed -$8.08M
ENTX icon
43
Entera Bio
ENTX
$97.6M
– –
-17,142
Closed -$33.3K
FOLD
44
DELISTED
Amicus Therapeutics
FOLD
– –
-352,896
Closed -$5.03M
FULC icon
45
Fulcrum Therapeutics
FULC
$243M
– –
-72,060
Closed -$815K
IVA
46
Inventiva
IVA
$1.09B
– –
-100,000
Closed -$465K
OCUL icon
47
Ocular Therapeutix
OCUL
$1.96B
– –
-418,080
Closed -$5.08M
PALI icon
48
Palisade Bio
PALI
$342M
– –
-367,103
Closed -$863K
QNCX icon
49
Quince Therapeutics
QNCX
$18.5M
– –
-4,294
Closed -$2.88M
RARE icon
50
Ultragenyx Pharmaceutical
RARE
$2.88B
– –
-31,738
Closed -$730K
1
2
3

Similar funds

GIM
Guild Investment Management Los Angeles, California $140M AUM 28.67% 1-Year Est. Return
SLWM
Stone Loft Wealth Management West Chester, Pennsylvania $140M AUM
NWA
Northwest Wealth Advisors Bellingham, Washington $140M AUM
WCM
WealthTrak Capital Management Virginia Beach, Virginia $140M AUM 17% 1-Year Est. Return
JD6
J Digital 6 Chicago, Illinois $140M AUM
CPC
CFC Planning Company Cicero, Indiana $140M AUM 22.33% 1-Year Est. Return
CFG
Chapman Financial Group Kailua, Hawaii $140M AUM 15.83% 1-Year Est. Return
RC
Rexford Capital Bellaire, Texas $140M AUM 28.19% 1-Year Est. Return

Superstring Capital Management's Q1 2026 Portfolio in Review

As of Q1 2026, Superstring Capital Management held 59 positions worth $140M, down 25% from $187M the previous quarter. Its ten largest holdings account for 58% of the portfolio.

Superstring Capital Management withdrew a net $52M in Q1 2026, closing 24 positions and reducing 12 holdings. Its most notable exit was Cidara Therapeutics, an estimated $18.8M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

Against the trend, Superstring Capital Management opened a new position in Summit Therapeutics worth $16.9M.

  • Superstring Capital Management's largest Q1 2026 buy was Summit Therapeutics: 892,873 shares worth $16.9M.
  • Superstring Capital Management added most to Genmab in Q1 2026, an estimated $5.02M increase.
  • Superstring Capital Management's biggest Q1 2026 reduction was UroGen Pharma, cutting an estimated $6.64M.
  • Superstring Capital Management fully exited Cidara Therapeutics in Q1 2026, selling an estimated $18.8M.
  • Superstring Capital Management's ten largest holdings make up 58% of its $140M portfolio in Q1 2026.
  • Superstring Capital Management opened 14 new positions and closed 24 in Q1 2026.
  • Superstring Capital Management's portfolio value fell 25% quarter-over-quarter to $140M.

Based on Superstring Capital Management's 13F filing for Q1 2026, filed 14 May 2026.